Op­ko in­sists that ‘out­liers’ screwed up its big PhI­II study on a Pfiz­er-part­nered ther­a­py

Near the be­gin­ning of this year, Op­ko Health shares $OPK took a dive when the com­pa­ny re­port­ed out that its Phase III study of a long-act­ing growth hor­mone part­nered with Pfiz­er had flopped. But it in­sist­ed that “out­liers” in the study may have cor­rupt­ed the re­sults.

To­day, Op­ko is in­sist­ing that these uniden­ti­fied “out­liers” are, in fact, the chief cul­prit for the fail. In a state­ment this morn­ing, the com­pa­ny re­port­ed:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.